Website
Alterity Therapeutics Ltd.Telephone
61.3.9349.4906
Address
Suite 4 Level 14 350 Collins Street Melbourne, Victoria (VIC) 3000
Description
Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.01
Trade Value (12mth)
AU$15,312.00
1 week
33.33%
1 month
33.33%
YTD
-42.86%
1 year
-33.33%
All time high
1.50
EPS 3 yr Growth
-42.20%
EBITDA Margin
N/A
Operating Cashflow
-$13m
Free Cash Flow Return
-68.60%
ROIC
-104.00%
Interest Coverage
N/A
Quick Ratio
3.50
Shares on Issue (Fully Dilluted)
4776m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.03
Date | Announcements |
---|---|
06 November 24 |
Alterity Announces Publication On ATH434 Mechanism of Action
×
Alterity Announces Publication On ATH434 Mechanism of Action |
31 October 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
23 October 24 |
Notice of Annual General Meeting
×
Notice of Annual General Meeting |
14 October 24 |
ATH to Participate in 2024 Maxim Healthcare Virtual Summit
×
ATH to Participate in 2024 Maxim Healthcare Virtual Summit |
11 October 24 |
Alterity Presents Data Describing Neuroprotection of ATH434
×
Alterity Presents Data Describing Neuroprotection of ATH434 |
04 October 24 |
Change of Share Registry
×
Change of Share Registry |
02 October 24 |
Alterity Data Presentations at MDS Congress Raises Profile
×
Alterity Data Presentations at MDS Congress Raises Profile |
30 September 24 |
ATH Appoints Abby Macnish Niven as Chief Financial Officer
×
ATH Appoints Abby Macnish Niven as Chief Financial Officer |
30 September 24 |
Alterity Therapeutics Filed Form 20-F and XBRL data with SEC
×
Alterity Therapeutics Filed Form 20-F and XBRL data with SEC |
26 September 24 |
Annual Report 2024
×
Annual Report 2024 |
26 September 24 |
Corporate Governance Statement
×
Corporate Governance Statement |
26 September 24 |
Appendix 4G
×
Appendix 4G |
23 September 24 |
Alterity to Deliver Multiple Presentations at MDS Congress
×
Alterity to Deliver Multiple Presentations at MDS Congress |
20 September 24 |
Change of Director's Interest Notice - BM / PM
×
Change of Director's Interest Notice - BM / PM |
02 September 24 |
Notification of cessation of securities - ATH
×
Notification of cessation of securities - ATH |
29 August 24 |
Appendix 4E Preliminary Final Report
×
Appendix 4E Preliminary Final Report |
01 August 24 |
Notification of cessation of securities - ATH
×
Notification of cessation of securities - ATH |
31 July 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
24 July 24 |
Alterity Therapeutics to Present at MST Financial Webinar
×
Alterity Therapeutics to Present at MST Financial Webinar |
19 July 24 |
Application for quotation of securities - ATH
×
Application for quotation of securities - ATH |
19 July 24 |
Notice Under Section 708A
×
Notice Under Section 708A |
18 July 24 |
Proposed issue of securities - ATH
×
Proposed issue of securities - ATH |
17 July 24 |
Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
×
Positive Interim Data from ATH434-202 Phase 2 Clinical Trial |
15 July 24 |
Trading Halt
×
Trading Halt |
28 June 24 |
Notification regarding unquoted securities - ATH
×
Notification regarding unquoted securities - ATH |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.